Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001596771-20-000113
Filing Date
2020-11-09
Accepted
2020-11-09 18:34:51
Documents
1
Period of Report
2020-11-05

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 4  
1 PRIMARY DOCUMENT primary_doc.xml 4 8421
  Complete submission text file 0001596771-20-000113.txt   10001
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Issuer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 5130 ROUTE 212 WILLOW NY 12495
Business Address
MANUSO JAMES S J (Reporting) CIK: 0001236365 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-34079 | Film No.: 201299152